Modulators of the interaction of Astrin and Raptor, and uses thereof in cancer therapy

Technology

Mammalian target of rapamycin complex 1 (mTORC1) controls growth and survival in response to metabolic cues. Oxidative stress affects mTORC1 via inhibitory and stimulatory inputs. Whereas downregulation of TSC1-TSC2 activates mTORC1 upon oxidative stress, the molecular mechanism of mTORC1 inhibition remains unknown. We identified Astrin as an essential negative mTORC1 regulator in the cellular stress response. Upon stress, Astrin inhibits mTORC1 association and recruits the mTORC1 component Raptor to stress granules (SGs), thereby preventing mTORC1-hyperactivationinduced apoptosis. In turn, balanced mTORC1 activity enables expression of stress factors. By identifying Astrin as a direct molecular link between mTORC1, SG assembly, and the stress response, we establish a unifying model of mTORC1 inhibition and activation upon stress. Importantly, we show that in cancer cells, apoptosis suppression during stress depends on Astrin. Being frequently upregulated in tumors, Astrin is a potential clinically relevant target to sensitize tumors to apoptosis.

Innovation

 Astrin-Raptor (mTORC1) interaction modifies apoptosis susceptibility of cancer cells

Application

 Targeting Astrin-Raptor interaction may be a relevant approach for drug development

Market Potential

The Astrin gene is amplified in a large number of tumors (cBIO database), including breast and non-small cell lung cancer. The mTORC1 network is altered in over 70% of all tumors (cBIO data base). Thus, many patients may be amenable to Astrin-Raptor based therapies.

Thedieck K, Holzwarth B et al. Inhibition of mTORC1 by Astrin and stress granules prevents apoptosis in cancer cells. **Cell (2013)** 15 Aug; 154 (4):859-874

Responsible Scientist

Prof. Dr. Kathrin Thedieck

Dept. of Pediatrics, University Medical Center Groningen (UMCG), NL

Branch

Pharma

Patent Status

Granted EP 2 755 027 B1 with HK US and JP patent application pending Filed (PRD) Jan. 11th 2013

Reference Number

ZEE20120821

Status: Sept -16

Contact

Dr. Claudia Skamel Campus Technologies Freiburg GmbH Stefan-Meier-Str. 8 | D-79104 Freiburg Email: Claudia.Skamel@campus-technologies.de Tel: +49 (0)761 203-4987 Fax:+49 (0)761 203-5021



CTF – The R & D Company of the Freiburg University and the Freiburg University Medical Center



